AstraZeneca saw £10bn ($12.7bn) wiped off its market value on 3 June after it posted disappointing early efficacy data from the TROPION-Lung01 trial of datopotamab deruxtecan (Dato-DXd), seen as a potential future market leader among TROP2-targeting antibody drug conjugates.
Can Gilead And Merck Capitalize On AstraZeneca/Daiichi Sankyo’s TROP2 Safety Concerns?
Dato-DXd’s Lung Adverse Events Could Scupper NSCLC Goals
AstraZeneca and Daiichi-Sankyo’s second collaboration has taken a knock after a mixed readout from the TROPION-Lung01 study of their antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), and its rivals will hope their differently engineered ADCs can win out in the long-term.
